Ovarian hyperstimulation syndrome

被引:3
作者
Le Gouez, A. [1 ]
Naudin, B. [1 ]
Grynberg, M. [2 ]
Mercier, F. -J. [1 ]
机构
[1] Univ Paris Sud, Hop Beclere, AP HP, Dept Anesthesie Reanimat, F-92141 Clamart, France
[2] Univ Paris Sud, Hop Beclere, AP HP, Serv Gynecol Obstet, F-92141 Clamart, France
来源
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION | 2011年 / 30卷 / 04期
关键词
Ovarian stimulation; Increased capillary permeability; VEGF; Third space; Assisted reproductive techniques; Thrombosis; ENDOTHELIAL GROWTH-FACTOR; INVITRO FERTILIZATION; ASSISTED CONCEPTION; RENIN-ACTIVITY; HUMAN ALBUMIN; SYNDROME OHSS; ASCITES; THROMBOPHILIA; STIMULATION; PREVALENCE;
D O I
10.1016/j.annfar.2010.11.026
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The ovarian hyperstimulation syndrome (OHSS) is a complication of controlled ovarian hyperstimulation (COH) protocols performed in women undergoing assisted reproductive technologies. This syndrome is characterized by multiple intra-ovarian corpus luteum and constitution of a third space that can lead to a life-threatening situation. Although the pathophysiology remains unclear, vascular endothelial growth factor (VEGF) and other cytokines, secreted under the influence of exogenous gonadotrophins administered for COH, are involved in increasing capillary permeability. The clinical course varies from increased size of the ovaries to anasarca with potentially fatal circulatory dysfunction. Mortality rate, though not accurately quantified, is significant (1/45 000 to 1/500 000) and mostly due to thromboembolic complications. The only effective treatment is prevention, by adapting ovarian stimulation protocols to OHSS risk factors. There are no specific treatments and therapy is mainly symptomatic until the condition resolves spontaneously. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:353 / 362
页数:10
相关论文
共 81 条
[1]   Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review [J].
Aboulghar, M ;
Evers, JH ;
Al-Inany, H .
HUMAN REPRODUCTION, 2002, 17 (12) :3027-3032
[2]  
ABOULGHAR M, 2002, COCHRANE DB SYST REV, V2
[3]  
ABOULGHAR MA, 1990, FERTIL STERIL, V53, P933
[4]   Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome [J].
Abramov, Y ;
Barak, V ;
Nisman, B ;
Schenker, JG .
FERTILITY AND STERILITY, 1997, 67 (02) :261-265
[5]   Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study [J].
Abramov, Y ;
Elchalal, U ;
Schenker, JG .
FERTILITY AND STERILITY, 1998, 70 (06) :1070-1076
[6]   Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report [J].
Abramov, Y ;
Fatum, M ;
Abrahamov, D ;
Schenker, JG .
FERTILITY AND STERILITY, 2001, 75 (06) :1228-1230
[7]   Febrile morbidity in severe and critical ovarian hyperstimulation syndrome: a multicentre study [J].
Abramov, Y ;
Elchalal, U ;
Schenker, JG .
HUMAN REPRODUCTION, 1998, 13 (11) :3128-3131
[8]   An 'epidemic' of severe OHSS: a price we have to pay? [J].
Abramov, Y ;
Elchalal, U ;
Schenker, JG .
HUMAN REPRODUCTION, 1999, 14 (09) :2181-2183
[9]   Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome [J].
Abuzeid, MI ;
Nassar, Z ;
Massaad, Z ;
Weiss, M ;
Ashraf, M ;
Fakih, M .
HUMAN REPRODUCTION, 2003, 18 (02) :370-373
[10]   Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction [J].
Alvarez, Claudio ;
Marti-Bonmati, Luis ;
Novella-Maestre, Edurne ;
Sanz, Roberto ;
Gomez, Raul ;
Fernandez-Sanchez, Manuel ;
Simon, Carlos ;
Pellicer, Antonio .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :2931-2937